A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

Clinical trial NCT04853017 · COMPLETED

Trial details

NCT number: NCT04853017
Sponsor: Elicio Therapeutics
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Minimal Residual Disease KRAS G12D KRAS G12R NRAS G12D NRAS G12R Pancreatic Ductal Adenocarcinoma Colorectal Cancer Non-small Cell Lung Cancer Ovarian Cancer Cholangiocarcinoma Bile Duct Cancer Gallbladder Carcinoma

Start date: 2021-10-04
Primary completion: 2023-01-26
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.